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the adequacy of tissue microarrays 
in the assessment of inter- and 
intra-tumoural heterogeneity of 
infiltrating lymphocyte burden in 
leiomyosarcoma
A. t. J. Lee  1,2, W. chew2, C. P. Wilding2, N. Guljar2, M. J. Smith1, D. C. Strauss1, C. fisher1, 
A. J. Hayes1, I. Judson1, K. thway1, R. L. Jones1,3 & p. H. Huang2
The characterisation and clinical relevance of tumour-infiltrating lymphocytes (TILs) in leiomyosarcoma 
(LMS), a subtype of soft tissue sarcoma that exhibits histological heterogeneity, is not established. The 
use of tissue microarrays (TMA) in studies that profile TIL burden is attractive but given the potential 
for intra-tumoural heterogeneity to introduce sampling errors, the adequacy of this approach is 
undetermined. In this study, we assessed the histological inter- and intra-tumoural heterogeneity in 
TIL burden within a retrospective cohort of primary LMS specimens. Using a virtual TMA approach, we 
also analysed the optimal number of TMA cores required to provide an accurate representation of TIL 
burden in a full tissue section. We establish that LMS have generally low and spatially homogenous TIL 
burdens, although a small proportion exhibit higher levels and more heterogeneous distribution of TILs. 
We show that a conventional and practical number (e.g. ≤3) of TMA cores is adequate for correct ordinal 
categorisation of tumours with high or low TIL burden, but that many more cores (≥11) are required to 
accurately estimate absolute TIL numbers. Our findings provide a benchmark for the design of future 
studies aiming to define the clinical relevance of the immune microenvironments of LMS and other 
sarcoma subtypes.
Tissue microarrays (TMAs) are useful diagnostic and research tools that permit high-throughput histological 
and molecular studies of up to several hundred tissue specimens simultaneously by arraying them into a paraffin 
block1. This approach offers several advantages over conventional examination of full tissue sections by minimis-
ing consumption of often limited tissue while providing various efficiencies in downstream sample processing 
and analysis. However, an inherent limitation to the use of TMAs is that, for each included specimen, only a 
small amount of tissue is sampled and arrayed, meaning that sampling error may lead to a distorted representa-
tion of the full tissue section. This limitation is of particular relevance in the study of tumour specimens, where 
intra-tumour spatial heterogeneity in terms of morphology and underlying molecular pathology is now well 
established in many cancer types2. Multiple studies have been undertaken to validate the TMA methodology in 
the assessment of various cancer biomarkers, with the aim of demonstrating that biomarker levels reported by 
TMAs are representative of results obtained when full sections are assessed. In this manner, it has been shown that 
expression levels of a diverse repertoire of tumour biomarkers are accurately reported through the assessment of 
TMAs, typically with the provision that between 1 and 3 replicate cores from each included tumour are assessed 
and aggregated3–6.
Investigating the immune microenvironment as a potential source of cancer biomarkers is an area of 
renewed research interest. It is now known that the presence or absence of immune-related factors such as 
tumour-infiltrating lymphocytes (TIL) can serve as powerful prognostic and/or predictive biomarkers across a 
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range of cancer types7–10. TMAs continue to be frequently employed in studies that seek to investigate the poten-
tial role of TILs as putative biomarkers7,11–15. The success of such studies is dependent on the ability of the TMA 
approach to capture a sufficiently representative picture of the immune phenotypes present within the wider 
tumour. Observations of quantitative and qualitative spatial heterogeneity in the immune microenvironment of 
individual tumours of various cancer types call into question how well TMAs can provide such representation 
and whether the scope for sampling error renders them inappropriate for studies of tumour immunity16–20. There 
is currently little published evidence addressing this question21–23.
In this study, we assessed a cohort of leiomyosarcoma (LMS) tumour specimens to investigate the extent of 
inter- and intra-tumoural heterogeneity of TIL burden and how accurately TIL burden are represented by the 
TMA methodology, compared to full tumour sections. LMS are tumours of smooth muscle lineage that can arise 
from the uterus or from other anatomic sites including vessel walls. LMS are one of the more common soft tissue 
sarcoma (STS) subtypes, representing 10–20% of all STS24. As with other STS subtypes, the immune microenvi-
ronment and its potential prognostic value is not well characterised in LMS. There is accumulating evidence that 
LMS is a disease that harbours extensive inter- and intra-tumoural genetic and morphological heterogeneity. For 
instance, recent genomic profiling analyses demonstrate that LMS is characterised by inter-tumour variability 
in somatic copy number alterations, a molecular characteristic found to have negative correlation with active 
anti-tumour immune response in a number of other cancers25,26. Furthermore, clinical evidence suggest that 
a small minority of LMS patients respond to immune checkpoint inhibitor therapy27–29. As such, inter-patient 
differences in the immune microenvironment of LMS may be useful for predicting response to therapy and prog-
nosis. LMS often present with large primary tumours that exhibit intra-tumoural morphological heterogeneity 
of tumour cells and associated stroma, and consequently may also display intra-tumoural TIL heterogeneity30. 
To assess the suitability of TMAs for profiling TIL burden in LMS, we sought to address two questions in this 
study: 1) What is the extent of inter- and intra-tumour heterogeneity of TIL burden in LMS, by comparing related 
tumour blocks from spatially distinct areas of primary tumours and 2) how many TMA cores are required to 
provide sufficient representation of the TIL burden of the full tissue section?
Materials and Methods
Tumour sample selection and processing. Surgical resection specimens of primary LMS (n = 47) and 
accompanying annotation of baseline clinicopathological variables were identified and retrieved through ret-
rospective review of departmental database and medical notes at a single specialist cancer centre. Histological 
diagnosis was confirmed by a specialist sarcoma histopathologist (CF, KT). Where available, 5 blocks contain-
ing formalin-fixed paraffin-embedded (FFPE) viable tumour from spatially distinct areas (at least 2 blocks 
each from tumour margins and core) of the same primary tumour were selected. Newly prepared haematox-
ylin and eosin (H&E) slides from each block were assessed to confirm presence of viable tumour material. 
Immunohistochemical (IHC) staining of T lymphocyte markers (anti-CD3 [clone M0452, DAKO, 1:600 dilu-
tion], anti-CD4 [4B12, DAKO, 1:80] and anti-CD8 [C8/144B, DAKO, 1:100]) was performed on consecutive 
4 µm sections from each block (See supplemental methods for further details). Human tonsillar tissue was used 
for positive control for expression of CD3, CD4 and CD8, with omission of primary antibody for negative control 
and use of Mouse IgG1 (X0931, DAKO, 1:80 or 1:100) or Rabbit IgG (ab172730, Abcam 1:600) for CD4/CD8 or 
CD3 isotype controls respectively. IHC staining for B lymphocytes (anti-CD20 [L26,DAKO, 1:400]) was per-
formed on all blocks from an initial set of 19 tumours – this was not expanded to all tumours due to uniformly 
low numbers of infiltrating B cells in this initial set.
iHc scoring. Full tissue sections. The number of CD3, CD4, CD8 and CD20 IHC-positive lymphocytes 
in ten non-adjacent, tumour-containing high-power fields (HPF) (x400 magnification, approx. area per HPF 
0.31 mm2) was manually counted by direct brightfield microscopy for each stained slide.
Virtual TMA (vTMA). Digital microscopy images for slides stained for H&E, CD3 and CD8 from a single 
block from each of 47 cases were captured at x40 resolution using Nanozoomer-XR (Hamamatsu Photonics). To 
generate a virtual TMA (vTMA), 1 mm diameter circular areas were selected from viable-tumour areas on each 
H&E image. For assessment of optimal number of cores, 20 × 1 mm areas were selected at random, while to assess 
for intra-tumoral variance between central and peripheral tumour regions, 20 × 1 mm areas were selected at both 
the tumour periphery (defined as within 3 mm of inked resection margin) and central (defined as ≥10 mm from 
nearest resection margin) regions. The corresponding areas were then selected on CD3 and CD8 digital slide 
images. Images of these areas at x10 magnification were exported as.tif files that were cropped to uniform 0.785 
mm2 circular areas in Image J31. TIL expression in these images were counted using ‘Particle analysis’ function 
of image J following optimization of pixel intensity, particle size and circularity thresholds. The selected configu-
ration was associated with a bias of −0.52 cells, with 95% limits of agreement at −17 to +16 cells, as assessed by 
Bland-Altman analysis. Due to the presence of pleomorphic, CD4-expressing histiocytes, we were unable to use 
this approach for counting of CD4+ TILs, and so this marker was not included in the vTMAexperiment.
Physical TMA (pTMA). To generate the physical TMA (pTMA), triplicate 1 mm diameter cores were sampled 
from areas of viable tumour within donor blocks from 44/47 LMS and re-embedded in an arrayed recipient 
paraffin block. Consecutive 4 µm sections from the arrayed block were stained for H&E, CD3 and CD8. After 
assessment of H&E slides to confirm viable tumour content, all CD3+ and CD8+ TILs were counted under direct 
brightfield microscopy. Average TIL number per 1 mm core (referred to herein as ‘TIL/core’) was calculated from 
triplicate cores for each tumour.
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Statistical analysis. Degree of infiltrating lymphocyte burden across LMS cohort. To assess the extent of 
TIL burden in each of 47 LMS cases, an average number of infiltrating CD3+, CD4+ and CD8+ TIL per HPF 
(referred to herein as ‘TIL/HPF’) was calculated from 50 HPF per tumour (10 HPF from each of 5 related tumour 
blocks). Comparison of TIL burden of tumours from different anatomical sites of origin and grade was performed 
using 1-way ANOVA of Log2-transformed average TIL/HPF values with Prism v7.0 (GraphPad Software Inc).
Inter- vs intra-tumour variance in TILs. To assess the variability in TIL burden between different blocks from 
the same surgical specimen, we assessed the relative contribution of inter-block variation (block effect) and 
inter-tumour variation (tumour effect) on the total amount of variance in TIL numbers within the 47 LMS cohort 
by (i) Log2 transformation of all raw TIL/HPF count values (ii) calculation of average TIL/HPF with 95% con-
fidence interval for each tumour block (average of 10 HPF), and across all 5 related blocks from each primary 
tumour (average of 50 HPF), and (iii) Ordinary 2 way ANOVA (Prism v7.0) to assess the percentage of total 
variability attributable to block effect, tumour effect, interaction between the two effects and residual variation. 
Correlation between Log2-transformed values for tumour average TIL/HPF and the standard deviation of aver-
age TIL/HPF of constituent blocks was assessed through calculation of Pearson correlation coefficients.
Virtual TMA assessment of optimal core number. Automated counts of infiltrating CD3+ and CD8+ TIL in all 
20 × 1 mm vTMA cores for each tumour were used to calculate average TIL/core – this value was taken as rep-
resenting the ‘true’ TIL burden of each tumour. Estimates of these true TIL burdens were then derived from the 
average TIL/core from all possible combinations of between 2 and 19 randomly-selected cores. The percentage 
of estimates generated from n cores that fell within the following prescribed boundaries were then calculated: 
a) within +/− 20% of true TIL burden; b) within correct (i.e. same as true TIL burden) side of dichotomised 
‘high/low’ boundary set at median of true TIL burdens from 47 LMS cohort; c) within correct quartile of 47 LMS 
cohort.
Virtual TMA assessment of intra-tumoral variance in TILs between tumour periphery and central regions. 
Automated counts of infiltrating CD3+ and CD8+ TIL in 20 × 1 mm vTMA cores were Log10-transformed 
and then used to derive sample frequency distributions, average TIL/core and standard deviation values from 
matched peripheral and central tumour areas in a subset of 6 tumours. Paired T tests were then performed to 
assess for differences between average TIL/core values from margin and core areas using Prism v7.0 (GraphPad 
Software Inc).
Assessment of accuracy of triplicate cores within a physical TMA (pTMA). The differences between 
Log2-transformed values of the estimated average TIL/core values derived from the pTMA and the true TIL bur-
dens derived from the vTMA were calculated and plotted against the average of the two values in a Bland Altman 
plot along with 95% levels of agreement (Prism v7.0).
Average of TIL/core values derived from triplicate cores within pTMA were used to identify each included 
LMS as having a ‘high’ or ‘low’ TIL burden, relative to the cohort median of true TIL burdens, as defined in the 
vTMA experiment. This high/low identification was then compared to a ‘gold standard’ high/low allocation, 
defined as the ‘true’ TIL burden of that tumour as derived from all 20 vTMA cores. Accuracy (%) of pTMA was 
defined as 100*(True Positive + True Negative)/(True Positive + False Positive + True Negative + False Negative)
Research ethics. Use of archival FFPE tumour samples and linked anonymised patient was approved by 
Institutional Review Board as part of the PROSPECTUS study, a Royal Marsden-sponsored non-interventional 
translational protocol (CCR 4371, REC 16/EE/0213).
Results
patient and tumour characteristics. Adequate tumour material was identified for 47 patients with a con-
firmed diagnosis of LMS who had undergone radical resection of primary tumour (baseline clinicopathological 
variables are summarised in Table 1). A majority of tumours were >5 cm in maximal dimension, and 21 (44%) 
were >10 cm. Six tumours (13%) were low grade.
LMS are variably infiltrated by T lymphocytes. For each case in the cohort, 5 tissue blocks that sam-
pled spatially distinct tumour areas were assessed for TIL burden (outlined in workflow in Fig. 1A). IHC expres-
sion for CD3 was used as a global T lymphocyte marker, with expression of consecutive slides for CD8 and 
CD4 used as markers for cytotoxic and helper T cell subpopulations respectively. CD20 expression was used as 
a global marker for B lymphocytes. Positive and negative controls were performed on tonsillar tissue (Fig. S1). 
Positive-staining TILs in 10 non-adjacent HPF were counted in sections from each of 5 blocks per tumour, with 
the average of all 50 related HPF (equating to a total area of 15.5 mm2 of assessed tumour) taken to represent the 
overall tumour TIL burden. Exemplar IHC images showing different degrees of CD3+ lymphocyte infiltration are 
shown in Fig. 1B. The distribution of overall tumour TIL burdens for each lymphocyte marker across the cohort 
is shown in Fig. 1C. The cohort medians of average TIL/HPF were CD3: 16.5 (IQR 11.3–30.9), CD4: 10.5 (IQR 
5.5–18.9), CD8: 16.1 (IQR 7.2–23.0). These median values are below the ‘low infiltration’ thresholds currently 
used in studies of TILs in other well-studied cancer types such as melanoma, non-small cell lung cancer (NSCLC) 
and colorectal cancer32–36.
A median CD20+ TIL/HPF of 0.3 (IQR 0.1–1.5), indicated the near-absence of infiltrating B cells in a subset 
of 19 tumours. Across the different T lymphocyte markers, a dynamic range of 2–3 orders of magnitude (e.g. CD3 
range 1–124 TIL/HPF) was seen in the extent of TIL burden between individual tumours (Fig. 1B). No significant 
differences in T lymphocyte burden was seen when comparing LMS from different anatomical sites of origin or 
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of different histological grade (Fig. 1D,E). These data indicate that marked variation in TIL burden is seen among 
individual LMS cases in a manner that was not associated with anatomical site of origin or grade, and that LMS 
generally have a lower TIL burden than other, well-studied epithelial tumour types.
Inter-tumour heterogeneity in TIL burden of LMS greatly outweighs intra-tumour heterogeneity. 
Having established that overall TIL burdens can vary between individual LMS tumours, we assessed the extent 
of heterogeneity in average TIL/HPF between blocks taken from different regions from the same LMS specimen 
(Fig. 1A).
Average TIL burden (stated as TIL/HPF) from each of 5 sampled blocks from the 47 cases are shown aligned 
with overall tumour average values in Fig. 2A. These data demonstrate that in most LMS cases, all the blocks 
from the same tumour had similar TIL/HPF values, suggesting low levels of intra-tumoural heterogeneity in 
these cases. However, in a subset of 10 cases (21%), TIL/HPF values varied widely between individual blocks 
from the same tumour, indicating higher levels of heterogeneity in TIL distribution. Differences in the extent of 
intra-tumoural TIL heterogeneity between individual LMS tumours is further exemplified in 3 cases, as illustrated 
in Fig. 2B. Notably, the tumours with the greatest extent of intra-tumour TIL heterogeneity tended to be those 
cases with the highest overall TIL burdens (Fig. 2A).
We performed 2-way ANOVA to objectively assess the relative extent that intra-tumoural heterogeneity (i.e. 
variation between blocks from the same tumour – ‘block effect’) and inter-tumoural heterogeneity (i.e. variation 
in overall TIL burdens between different tumours – ‘tumour effect’) contributed to the overall amount of varia-
tion in TIL burden within the cohort (Fig. 2C). We found that block effect had a much smaller contribution to 
the overall amount of variance compared to the contribution of tumour effect between cases within the cohort. 
Tumour effect accounted for 54.1%, 53.7% and 55.5% of total variance in lymphocyte counts for CD3, CD4 and 
CD8 respectively, while block effect contributed to only 0.3%, 0.5% and 0.7% total variance for the same respec-
tive markers. Significant interaction between tumour and block effect was detected for all three T lymphocyte 
measurements, in keeping with the observation that a greater degree of intra-tumour variance is observed in 
tumours with higher TIL burdens. The association between TIL density and spatial heterogeneity was further 
demonstrated by the strong positive correlation between tumour average TIL/HPF and the variance of average 
TIL/HPF between individual constituent blocks (Fig. S2).
Taken together, these results indicate that while intra-tumoural heterogeneity was observed in a subset of 
LMS cases with higher overall TIL levels, intra-tumoural heterogeneity in TIL burden across the cohort was out-
weighed by the extent of inter-tumoural heterogeneity.
Optimal number of cores to ensure representativeness of tissue microarrays depends on 
required degree of accuracy. To address the question of how many TMA cores must be sampled from a 
tumour to provide adequate representation of the overall TIL burden of a tumour, we devised an in silico ‘virtual 
TMA’ (vTMA) that would allow for the iterative sampling of a number of cores that would be impractical for a 
physical TMA. We then assessed how many cores were required to produce an estimate of TIL burden that either 
(i) accurately recapitulated the true TIL burden of a tumour, or (ii) was sufficiently accurate to identify whether 
a tumour had high or low TIL burden, relative to the median or quartile TIL values of the entire cohort– this 
second approach was based on the observation that, in many published studies that have demonstrated clinical 
relevance of TIL numbers, similar rank-based categorisation was used, often based on dichotomisation around 
cohort median value36.
For each of 47 LMS cases, digital microscopy images were taken of H&E, CD3 and CD8 stained whole sections 
of a single tumour block. 20 × 1 mm circular ‘core’ areas (total area. 15.7 mm2 - equivalent to approximately 50 
N (%)
Overall
Intra-cavity (exc. 
Uterine) Uterine Extremity/Trunk
47 27 (57%) 8 (17%) 12 (26%)
Anatomical position —
RP − 20 (74%)
—
Lower limb − 6 (50%)
AP- 7 (26%) Upper limb − 3 (25%)
Trunk − 3 (25%)
Average age/years (range) 61.5 (29.4–87.5) 62.2 (30.6–87.0) 46.4 (29.4–73.4) 69.8 (53.2–87.5)
% M:F 51:49 48:52 0:100 83:17
Max tumour dimension:
<5 cm 5 (11%) 2 (7%) 1 (13%) 1 (8%)
5–10 cm 21 (45%) 12 (44%) 3 (38%) 6 (50%)
10–15 cm 10 (21%) 6 (22%) 1 (13%) 3 (25%)
>15 cm 11 (23%) 7 (26%) 3 (38%) 1 (8%)
Histological grade:
1 6 (13%) 6 (22%) 0 0
2 25 (53%) 16 (59%) 3 (38%) 6 (50%)
3 16 (34%) 5 (19%) 5 (62%) 6 (50%
Table 1. Baseline clinicopathological status of 47 patients with primary LMS. RP = retroperitoneal. 
AP = abdominopelvic.
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Figure 1. Evaluation of infiltrating T and B lymphocyte burden in LMS. (A) Workflow of experimental 
approach. (B) Representative areas from different CD3-stained LMS demonstrating range of infiltrating CD3+ 
T lymphocyte burdens. Densities are (i) 1, (ii) 35, (iii) 100, (iv) 250 and (v) 800 TIL/HPF (vi) positive control 
tissue (appendix) with 1400 TIL/HPF. (C) Tukey box and tail plots showing overall lymphocyte burdens 
(average number of tumour-infiltrating lymphocytes (TIL) per x400 high-powered fields (HPF), calculated 
from 50 HPF) in LMS cohort based on IHC staining for CD3, CD4, CD8 (n = 47) and CD20 (n = 19) of LMS 
(D) Tukey box and tail plots showing distribution of CD3+, CD4+ and CD8+ TIL burdens within 47 LMS 
cohort when stratified by site of tumour origin. 1-way ANOVA of Log2-transformed values demonstrates no 
significant differences in T lymphocyte counts between tumours of different site of origin. (E) Tukey box and 
tail plots showing distribution of CD3+, CD4+ and CD8+ TIL burdens within 47 LMS cohort when stratified 
by grade of tumour. 1-way ANOVA demonstrated no significant difference in TIL count based upon tumour 
grade for CD3, CD4 and CD8 lymphocytes.
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Figure 2. Assessment of inter- and intra-tumour heterogeneity of TIL burden in LMS. (A) Dot plot shows 
average CD3+, CD4+ and CD8+ TIL/HPF values for each of 47 LMS tumours (vertically aligned), with 
overall tumour value (+/−95% confidence interval) and individual constituent blocks values shown with in 
black and red respectively. Colour bars demonstrate maximum difference of any related tumour block from 
overall tumour average, with zero, cohort interquartile range (IQR), and maximum difference values shown 
on colour key for each lymphocyte marker. (B) Representative IHC images at x20 magnification demonstrate 
CD3+ TIL burden between the most and least densely infiltrated blocks from three tumours as indicated in (A). 
(C) Table summarising results from three separate 2-way ANOVA analyses that identifies the contribution of 
intra-tumour (block effect) and inter-tumour (tumour effect) variance to the overall total amount of variance in 
lymphocyte counts for CD3, CD4 and CD8 within the 47 LMS cohort.
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HPF) were selected on H&E images, with the number of TILs within the corresponding areas (TIL/core) on CD3 
and CD8 stained slides digitally counted (Fig. 3A). For each tumour, the average TIL/core from each of every pos-
sible combination of 2 out of 20 cores, 3 out of 20 cores, and so on, were calculated (Fig. 3B). The average TIL/core 
of all 20 cores was taken to represent the ‘true’ overall TIL burden of each tumour. For each of the 47 tumours, 
we assessed how many cores needed to be sampled in order for >80% of possible combinations to produce an 
estimated TIL burden that fell within each of three different thresholds: (i) +/−20% of true TIL burden, (ii) same 
side of cohort median or (iii) in same cohort quartile as true TIL burden across the entire cohort (Fig. 3C).
A median of 11 cores (CD3 range 4–16, CD8 range 4–17) was required for >80% of estimated TIL burdens 
to fall within 20% of the ‘true’ CD3+ or CD8+ TIL burden for the corresponding tumour (Fig. 3D). However, 
for the majority of cases, only 1 core was required for >80% of estimated CD3+ or CD8+ TIL burdens to fall the 
same side of the cohort median as the corresponding true TIL burden. Similarly, a lower number of cores (median 
of 5 and 3 cores for CD3 and CD8 respectively) were required for >80% of estimated TIL burdens to fall in the 
same cohort quartile as the corresponding ‘true’ TIL burden. A minority of tumours required a greater number 
of cores for >80% of estimated TIL burdens to fall on the correct side of cohort median (8/47 and 6/47 requiring 
≥8 cores for CD3 and CD8 respectively), primarily due to these tumours having true TIL burdens that lay close 
to median cut-off values (Fig. 3D).
Taken together, these data indicate that a large and likely impractical number of TMA cores (11 cores) must be 
sampled in order to accurately recapitulate the true burden of infiltrating T lymphocytes in LMS. However, many 
studies that have described an association between TILs and clinical outcome ultimately applied cut-off thresh-
olds to assign TIL counts into ordinal categories (e.g. ‘high’ or ‘low’ infiltration) that reflect relative rather than 
absolute degree of infiltration36. We found that sampling only 1 core was sufficient to correctly identify a majority 
of tumours as has having a ‘high’ or ‘low’ degree of infiltration, while 2–5 cores was adequate to correctly identify 
a majority of tumours as having ‘very low’, ‘low’, ‘high’ or ‘very high’ degree of TIL infiltration, based on categor-
ical cut-offs at cohort quartiles. These data demonstrate that TMAs that include a practical number of replicate 
cores as used in previously reported studies (e.g. 3 or fewer) would be sufficiently representative when ordinal 
categorisation of TIL burden is planned. However, should precise quantification of the absolute value of true TIL 
burden be desired, a conventional TMA approach is unlikely to provide an adequate representation.
TIL levels vary between the tumour periphery and central regions. It has previously been shown 
that there are differences in TIL levels between the tumour core versus the invasive margin in colon cancer7,33. In 
order to assess the degree of variability in TILs between the tumour periphery and central regions in our study, 
a subset of 6 LMS cases were subjected to a vTMA workflow (outlined in Fig. S3A) where 20 × 1 mm digital 
microscopy cores were sampled within 3 mm of the inked resection margin (periphery) and a further 20 × 1 mm 
cores sampled at least 10 mm from the inked margin (central). The number of TILs within the corresponding 
areas (TIL/core) on CD3 and CD8 stained slides were digitally counted. There was variation in CD3+ TIL levels 
between these two regions with 4/6 cases showing statistically significant differences (Fig. S3B). Notably, there 
was no consistency in the TIL level differences between the two regions with 2/4 cases (LMS03 and LMS23) 
showing an increase in the periphery versus the centre and 2/4 cases (LMS04 and LMS11) had an increase in the 
central compared to the peripheral regions (Fig. S2B). Assessment of CD8+ TIL levels similarly finds that 4/6 
cases had statistically significant differences between the periphery and central tumour regions. In this instance, 
2/4 cases (LMS03 and LMS05) had an increase in CD8+ TILs in the periphery versus the central region while 
2/4 cases (LMS09 and LMS23) had an increase in the central compared to the peripheral region (Fig. S4A). Given 
the variation in TILs levels between these two distinct regions, this vTMA experiment found that there was no 
statistical significant difference in TIL levels between the periphery and central regions across the 6 LMS cases 
analysed (Figs S3C and S4B).
Triplicate TMA cores provide adequate sampling for the classification of LMS as containing high 
or low TIL burden. To validate our finding from the vTMA experiment that a conventional and practical 
number of TMA cores was sufficient for categorising tumours as having ‘high’ or ‘low’ TIL burden, we con-
structed a physical TMA (pTMA) that included triplicate 1 mm cores from sampled tumours. Forty-four out of 47 
LMS cases were included in this TMA. In 11/44 (25%) tumours, the same block was used for pTMA construction 
as was used for the vTMA model. In 33/44 (75%) tumours, due to insufficient tissue depth remaining in blocks 
used for the vTMA, a different tumour block from the same specimen was used for core sampling for the pTMA.
In the vTMA model, a median of 11 cores were required to accurately estimate the absolute value for true TIL 
burden. We thus assessed if the triplicate cores used in pTMA were similarly inaccurate in estimating absolute true 
TIL burdens (defined as the mean of all 20 cores from the vTMA experiment as shown in Fig. 3C) (Fig. 4A–C). 
Comparison of pTMA estimates to true TIL burdens using the Bland-Altman method for all 44 LMS cases indi-
cated that the pTMA produced a modest overestimate of ‘true’ TIL burden (pTMA bias +46% for CD3, +9% 
for CD8), but that levels of agreement between pTMA-derived estimates and true TIL burdens were poor. The 
wide 95% limits of agreement detected in this analysis indicated that for any pTMA-derived estimate within the 
cohort, there would be 95% confidence that the associated ‘true’ TIL burden was anything from 6–8 times less or 
9–14 times more than the estimate. These levels of agreement were improved when analysis was limited to the 11 
tumours where pTMA and vTMA were taken from the same tumour blocks (95% CI of true TIL burden between 
2 times less to 3 times more than the estimated value). This suggests that inter-block heterogeneity of TIL burden 
(i.e. block effect) likely contributed to the inaccuracy of pTMA estimates in cases where pTMA and vTMA were 
sampled from separate blocks. These data show that in pTMA estimates that are based on triplicate core sampling, 
block effects have a dramatic impact on absolute TIL enumeration and do not accurately estimate the true TIL 
burden, a finding that is consistent with results from the vTMA model.
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Figure 3. Optimal number of TMA cores relates to required degree of accuracy for assessment of lymphocyte 
infiltration. (A) Overview diagram of process for selection of virtual TMA cores and T lymphocyte counting. 
For each of 47 LMS, a digital H&E slide from a representative block was marked for 20 × 1 mm diameter areas, 
encompassing spatial and any morphological heterogeneity with section. Selected core areas were mapped on 
to corresponding CD3 and CD8-stained sections. Core areas were isolated as individual digital images. Number 
of IHC-positive lymphocytes in each core area was digitally counted. (B) Bar chart showing number of possible 
combination of cores when between 2–20 cores are assessed. Average lymphocyte count per core (TIL/core) was 
calculated for all possible combinations for each tumour. (C) Dot plot showing all possible average lymphocyte 
counts (number indicated in (B) for a single exemplar tumour when 1–20 cores are selected. Average of all 
20 cores (red dot) taken to be represent overall TIL burden for that tumour. For each tumour, the number of 
cores that needed to be sampled in order for >80% calculated averages to fall within either (i) +/−20% of ‘true 
TIL burden’ for corresponding tumour, (ii) correct side of cohort median TIL value (CD3 median = 69 TIL/
9Scientific RepoRtS |         (2019) 9:14602  | https://doi.org/10.1038/s41598-019-50888-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
In the vTMA experiment, a median of 1 core was needed to correctly identify a LMS tumour has having a 
‘high’ or ‘low’ CD3+ or CD8+ TIL burden, as defined by position above or below cohort median value. When 
triplicate cores within the pTMA were used to similarly assign tumours as having ‘high’ or ‘low’ TIL burdens (as 
per cohort median values, shown in Fig. 3C), we found good levels of agreement with assignment versus the true 
TIL burden (Fig. 4D–E). Across all 44 tumours represented in the pTMA, accuracy (i.e. percentage of tumours 
that were correctly identified as having ‘high’ or ‘low’ true TIL burden) was 70.5% and 90.9% for CD3 and CD8 
respectively. When limited to the 11 cases where the same block was used for both vTMA and pTMA, accuracy 
for correct identification of CD3+ or CD8+ TIL burden was improved to 72.7% and 100% respectively. Accuracy 
for the 33 cases where different blocks were used between vTMA and pTMA was 70.0% and 87.9%. These results 
demonstrate that, for a large majority of tumours in the cohort, triplicate TMA cores were adequate for correctly 
identifying whether the tumour had a ‘high’ or ‘low’ TIL burden. The accuracy of the pTMA for this ordinal cat-
egorisation was only modestly improved in tumours where the same tumour block was sampled for vTMA and 
pTMA, again indicating that there is only a minor contribution of intra-tumoural heterogeneity between related 
blocks to sampling error. This suggests that, for a majority of tumours, intra-tumoural heterogeneity between 
related blocks may not be a major source of sampling error for categorisation of high or low TIL burdens.
Consistent with the conclusions of the vTMA experiment (Fig. 3D), these findings show that the inclusion of 
a conventional and practical number of replicate cores from the same tumour (i.e. 3 cores) in a pTMA provides 
sufficient representation of true tumour TIL burden to accurately categorise tumours as having high or low TIL 
numbers, and that this accuracy is maintained between different blocks from the same tumour. However, the use 
of this relatively small number of cores can produce significant inaccuracy in estimating the absolute value of 
true TIL burden within a tumour in a manner that is compounded by both inter- and intra-block heterogeneity.
Discussion
In this study, we have characterised the TIL burden in a cohort of primary LMS tumours and demonstrate that 
there is evidence for both inter- and intra-tumoural heterogeneity in this STS subtype. We find that the TIL 
burden in LMS is generally low compared to immune-active cancer types such as melanoma and NSCLC, but 
that a subset of LMS exhibit heavier lymphocytic infiltration. Large intra-tumoural variation in TIL burden was 
observed in a minority of cases, particularly in tumours with a greater overall degree of TIL burden. However, 
across the whole cohort, the degree of intra-tumoural heterogeneity was small relative to the inter-tumoural 
differences in overall TIL burden between cases within the cohort. Additionally, our investigation of TMA meth-
odologies indicates that a conventional and practical number of replicate 1 mm cores provides sufficient rep-
resentation for ordinal categorisation of tumours as having either a high or low degree of lymphocyte infiltration 
– in our pTMA experiment, 3 × 1 mm provided accurate categorisation, while our vTMA results indicate that as 
few as a 1 × 1 mm core may be adequate. These data indicate that intra-tumour heterogeneity of TIL burden may 
not be a great source of confounding sampling error and that TMAs represent a feasible and appropriate research 
tool for future immune profiling studies in LMS.
Our finding that TIL burdens are generally low in LMS is consistent with other studies that have used histo-
logical or gene expression deconvolution approaches to profile immune responses in LMS and other STS sub-
types25,37–39. We also observe that a small number of LMS cases contain a higher degree of lymphocytic infiltrate 
and further studies in larger LMS cohorts are required to assess whether such differences in TIL burden can 
provide prognostic information or serve as predictive biomarkers for immunotherapies and/or other treatment 
modalities. Reported data have indicated that the biological and clinical relevance of TIL and other immune 
factors may vary between different STS subtypes25,38–40 – our focus on a single, more common STS subtype ena-
bles interpretation of our results without potential confounding by histological subtype-specific variation. LMS 
are typically subclassified by tumour grade and anatomical site of origin – in our limited cohort, we found no 
association between these characteristics and TIL burden. It remains to be seen whether there is any association 
between TIL burden or other immune micro-environment factors and proposed molecular LMS subtypes, which 
transcend conventional clinico-pathological categorisations.
The applicability of our findings to other STS or epithelial cancers remains to be determined. Intra-tumoural 
heterogeneity in the immune microenvironment has been described in numerous epithelial cancer types, both 
within primary lesions and between different metastatic sites7,11–15. In breast cancer, a vTMA methodology was 
used to demonstrate that agreement between TMA and whole tumour assessment of TIL burden plateaued when 
sampling any more than four 0.6 mm cores23. Interestingly, the degree of this correlation varied depending upon 
breast cancer subtype – Her2+ breast cancers had generally worse correlation, indicating greater spatial heter-
ogeneity in TIL distribution – and that a greater degree of TIL ‘skewness’ (i.e. greater spatial heterogeneity) was 
itself independently associated with worse prognosis. This suggests that spatial uniformity of TIL burden may 
vary between different cancer types and within different molecular and histological subtypes, and that spatial 
distribution itself may provide clinically relevant information, both findings that warrant caution when adopting 
core; CD8 median = 59 TIL/core), or (iii) within correct cohort quartile (CD3 IQR = 18–110 TIL/core; CD8 
IQR = 19–121 TIL/core). In this illustrated exemplar case, overall CD3+ TIL burden is above 3rd quartile 
(Q75 = 110). (D) Colour plots indicating percentage of systematically calculated average lymphocyte counts 
from all possible combinations of between 1–20 cores to fall within stated threshold (+/−20%, cohort median 
or cohort quartile). Blue arrows indicate exemplar case shown in C. Tukey box and tail plots indicate cohort 
distribution of number of cores required for >80% of estimates to fall within stated threshold. Table summarises 
cohort median number of cores required >80% of estimates to fall within stated threshold (+/− approx. 95% 
confidence interval).
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TMA methods for assessing TIL burden. Immune microenvironment-based biomarkers that have been described 
in colorectal and breast cancers depend upon intra-tumoural spatial distinction of TIL, where comparison of 
infiltrates between the tumour core or invading margin, or between tumour nests and stromal components, have 
been shown to be important considerations7,8. In our study, we find that across the 6 cases analysed, there was no 
significant difference in TIL burden between tumour periphery and central regions. Comparative analysis indi-
cates variation in TIL levels with some cases showing higher TIL levels in the periphery versus the core and others 
presenting the opposite observation. Cohen et al., have recently shown in a small cohort of 11 LMS cases that 
CD3+ TILs were present in both the central (11/11) and periphery (9/9) regions of the tumour. In their study, 
CD8+ TILs were found in a subset of cases in the central (10/11) and periphery (7/9) of the tumour41. Given the 
Figure 4. Triplicate TMA cores can identify tumours as having a high or low TIL burden, but do not accurately 
estimate precise TIL numbers. Bland Altman plots show percentage difference of pTMA-derived estimated TIL 
burdens compared to true TIL burdens for (A) CD3 and (B) CD8. 95% limits of agreement (LOA) for all 44 
tumours shown by black dotted lines, 95% LOA for 11 tumours with pTMA and vTMA from same block shown 
by red dotted lines. LOA and biases from these plots are summarised in (C). Dot plots show ratio of pTMA-
derived estimated TIL burden:cohort median value (x axis) plotted against ratio of true TIL burden:cohort 
median value (y axis) for (D) CD3+ and (E) CD8+ TILs. Ratio >0 indicates tumour identified as ‘High TIL 
burden’ (i.e above cohort median). Ratio <0 indicated tumour identified as ‘Low TIL burden’. Values in top right 
or bottom left quadrant (green boxes) indicate consistent TIL categorisation based on pTMA-derived estimate 
and true TIL burden. Red dots represent tumours where pTMA and vTMA sampled from same tumour block, 
black dots represent tumours where pTMA and vTMA were sampled from different blocks from same tumour 
specimen.
1 1Scientific RepoRtS |         (2019) 9:14602  | https://doi.org/10.1038/s41598-019-50888-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
small number of cases assessed in both studies, further evidence in larger cohorts is required to determine if these 
observations are generally applicable to LMS and other STS subtypes.
While TILs are accepted as central mediators of anti-tumour immune responses, the immune-tumour 
microenvironment constitutes a broad and complex range of cellular and protein factors that actively determine 
the nature and clinical consequence of any tumour-related immune response42. Our study does not provide any 
direct information on the use of TMAs to assess non-TIL immune factors and the extrapolation of our findings 
beyond TILs remains to be investigated.
Our data indicate that TMAs can provide a degree of representation of overall tumour TIL burden which 
is adequate for ordinal categorisation into high or low subgroups. The design of future studies of the immune 
microenvironment of tumours should acknowledge the inherent limitations of TMA methods and consider the 
incorporation of additional orthogonal approaches such as gene expression analysis and flow cytometry method-
ologies that are capable of providing complementary information regarding the composition of immune subsets 
leading to a more comprehensive and accurate representation of tumour immune microenvironment.
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